Suppr超能文献

体外模型中影响对利奈唑胺耐药性出现的药代动力学/药效学因素。

Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model.

作者信息

Boak Lauren M, Li Jian, Rayner Craig R, Nation Roger L

机构信息

Facility for Anti-Infective Drug Development and Innovation, Victorian College of Pharmacy, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia.

出版信息

Antimicrob Agents Chemother. 2007 Apr;51(4):1287-92. doi: 10.1128/AAC.01194-06. Epub 2007 Jan 22.

Abstract

Emerging resistance threatens the usefulness of linezolid for the treatment of severe infections caused by multidrug-resistant gram-positive bacteria. Optimal pharmacokinetic (PK)/pharmacodynamic (PD) indices have been described for the antimicrobial efficacy of linezolid (area under the concentration-time curve over 24 h at steady state divided by the MIC, >100; the cumulative percentage of a 24-h period that the drug concentration exceeds the MIC under steady-state PK conditions, >85). The aim of this study was to investigate the influence of these PK/PD indices on the development of resistance to linezolid by using an in vitro PK/PD model. Four dosage regimens were simulated over 72 h (two intermittent bolus regimens of 600 mg every 12 h [q12h] and 120 mg q12h and two continuous-infusion regimens of 120 mg/24 h and 30 mg/24 h) against four reference strains: methicillin-resistant Staphylococcus aureus (MRSA), heteroresistant vancomycin-intermediate S. aureus (hVISA), vancomycin-intermediate S. aureus (VISA), and vancomycin-resistant Enterococcus faecium (VRE). Linezolid concentrations were measured by high-performance liquid chromatography. Changes in susceptibility were characterized by pre- and posttreatment MIC measurements and population analysis profiles (PAPs). The linezolid concentrations that were achieved closely matched those that were targeted. The simulation with 600 mg q12h provided a >3-log10 reduction in the number of CFU/ml for all four strains, as did the 120-mg-q12h regimen for hVISA and VISA and the 30-mg/24-h continuous infusion for VRE and VISA. After 72 h of exposure to the 120-mg/24-h continuous-infusion simulation, the area under the PAP curve for all strains increased substantially (40 to 178%); increases in the MICs for the MRSA and hVISA strains were observed. The results demonstrate that PK/PD considerations are important in optimizing both antibacterial activity and the development of resistance to linezolid. The potential for resistance development appears to be higher when a constant concentration is maintained in the vicinity of the MIC of the bacteria.

摘要

新出现的耐药性威胁着利奈唑胺治疗由多重耐药革兰氏阳性菌引起的严重感染的有效性。利奈唑胺抗菌疗效的最佳药代动力学(PK)/药效学(PD)指标已被描述(稳态下24小时浓度-时间曲线下面积除以最低抑菌浓度,>100;稳态PK条件下药物浓度超过最低抑菌浓度的24小时累积百分比,>85)。本研究的目的是通过体外PK/PD模型研究这些PK/PD指标对利奈唑胺耐药性发展的影响。针对四种参考菌株(耐甲氧西林金黄色葡萄球菌(MRSA)、异质性万古霉素中介金黄色葡萄球菌(hVISA)、万古霉素中介金黄色葡萄球菌(VISA)和万古霉素耐药粪肠球菌(VRE))在72小时内模拟了四种给药方案(每12小时600毫克的两种间歇推注方案[q12h]和每12小时120毫克,以及每24小时120毫克和每24小时30毫克的两种持续输注方案)。通过高效液相色谱法测量利奈唑胺浓度。通过治疗前和治疗后最低抑菌浓度测量以及群体分析谱(PAP)来表征敏感性变化。所达到的利奈唑胺浓度与目标浓度紧密匹配。每12小时600毫克的模拟对所有四种菌株的CFU/ml数量减少了>3个对数10,每12小时120毫克的方案对hVISA和VISA以及每24小时30毫克的持续输注对VRE和VISA也是如此。在暴露于每24小时120毫克的持续输注模拟72小时后,所有菌株的PAP曲线下面积大幅增加(40%至178%);观察到MRSA和hVISA菌株最低抑菌浓度增加。结果表明,在优化抗菌活性和利奈唑胺耐药性发展方面,考虑PK/PD很重要。当在细菌最低抑菌浓度附近维持恒定浓度时,耐药性发展的可能性似乎更高。

相似文献

1
Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model.
Antimicrob Agents Chemother. 2007 Apr;51(4):1287-92. doi: 10.1128/AAC.01194-06. Epub 2007 Jan 22.
3
Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis.
Ann Pharmacother. 2005 Mar;39(3):427-32. doi: 10.1345/aph.1E484. Epub 2005 Feb 8.
4
Linezolid pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model.
Int J Antimicrob Agents. 2009 Mar;33(3):251-4. doi: 10.1016/j.ijantimicag.2008.09.006. Epub 2008 Dec 17.
6
Clinical pharmacokinetic/pharmacodynamic profile of linezolid in severely ill intensive care unit patients.
Int J Antimicrob Agents. 2011 Oct;38(4):296-300. doi: 10.1016/j.ijantimicag.2011.05.007. Epub 2011 Jul 8.
7
In vitro analysis of resistance selection by linezolid in vancomycin-susceptible and -resistant Enterococcus faecalis and Enterococcus faecium.
Int J Antimicrob Agents. 2009 Jul;34(1):21-4. doi: 10.1016/j.ijantimicag.2008.12.011. Epub 2009 Feb 24.
8
Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion.
Int J Antimicrob Agents. 2008 Feb;31(2):122-9. doi: 10.1016/j.ijantimicag.2007.09.009. Epub 2007 Dec 4.

引用本文的文献

1
Enhanced efficacy of sequential administration of fosfomycin and linezolid against .
Front Microbiol. 2025 Mar 17;16:1511707. doi: 10.3389/fmicb.2025.1511707. eCollection 2025.
6
Dose Optimization of Combined Linezolid and Fosfomycin against by Using an Pharmacokinetic/Pharmacodynamic Model.
Microbiol Spectr. 2021 Dec 22;9(3):e0087121. doi: 10.1128/Spectrum.00871-21. Epub 2021 Dec 1.
7
Optimization of Linezolid Dosing Regimens for Treatment of Vancomycin-Resistant Enterococci Infection.
Infect Chemother. 2021 Sep;53(3):503-511. doi: 10.3947/ic.2021.0034. Epub 2021 Jul 28.
8
Determining therapeutic trough ranges for linezolid.
Saudi Pharm J. 2019 Dec;27(8):1061-1063. doi: 10.1016/j.jsps.2019.09.002. Epub 2019 Sep 25.
9
Impact of erythrocytes on bacterial growth and antimicrobial activity of selected antibiotics.
Eur J Clin Microbiol Infect Dis. 2019 Mar;38(3):485-495. doi: 10.1007/s10096-018-03452-4. Epub 2019 Jan 28.
10
Pharmacokinetics and pharmacodynamics of Linezolid in burn patients.
Ann Burns Fire Disasters. 2018 Jun 30;31(2):118-121.

本文引用的文献

1
Linezolid-resistant Staphylococcus aureus in two pediatric patients receiving low-dose linezolid therapy.
Pediatr Infect Dis J. 2006 Jun;25(6):562-4. doi: 10.1097/01.inf.0000219401.70804.1a.
3
Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis.
J Antimicrob Chemother. 2004 Mar;53(3):441-4. doi: 10.1093/jac/dkh119. Epub 2004 Feb 12.
6
Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme.
Clin Pharmacokinet. 2003;42(15):1411-23. doi: 10.2165/00003088-200342150-00007.
8
The mutant selection window and antimicrobial resistance.
J Antimicrob Chemother. 2003 Jul;52(1):11-7. doi: 10.1093/jac/dkg269. Epub 2003 Jun 12.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验